IRLAB Therapeutics Logo

IRLAB Therapeutics

IRLAB | ST

Overview

Corporate Details

ISIN(s):
SE0012675361 (+1 more)
LEI:
549300JAT34LHEI0DH60
Country:
Sweden
Address:
Arvid Wallgrens backe 20, 413 46 Göteborg
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

IRLAB Therapeutics is a drug discovery and development company focused on creating novel treatments for neurodegenerative conditions and disorders of the central nervous system (CNS), with a primary emphasis on Parkinson's disease. The company leverages its proprietary and resource-efficient research platform, the Integrative Screening Process (ISP), to generate its drug pipeline. The ISP platform is built on a systems pharmacology discovery approach and utilizes an extensive, unique database of CNS compounds. Key clinical-stage candidates include Mesdopetam (IRL790), in development for treating levodopa-induced dyskinesia (LIDs), and Pirepemat (IRL752), aimed at treating impaired balance and falls associated with Parkinson's disease.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for IRLAB Therapeutics. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-11 09:00
Board/Management Information
IRLAB's CFO Viktor Siewertz leaves the company for a new leading position
English 39.6 KB
2025-08-11 09:00
Board/Management Information
IRLAB:s CFO Viktor Siewertz lämnar bolaget för ny ledande position
Swedish 40.0 KB
2025-07-18 18:31
Share Issue/Capital Change
IRLAB announces the outcome of the company’s rights issue
English 64.4 KB
2025-07-18 18:31
Share Issue/Capital Change
IRLAB offentliggör utfall i bolagets företrädesemission
Swedish 64.4 KB
2025-07-14 07:00
Share Issue/Capital Change
Sista dag för handel med teckningsrätter i IRLAB:s företrädesemission
Swedish 55.9 KB
2025-07-14 07:00
Share Issue/Capital Change
Last day of trading in subscription rights in IRLAB’s rights issue
English 56.0 KB
2025-07-03 07:00
Share Issue/Capital Change
The subscription period in IRLABS’s rights issue of shares commence today
English 57.2 KB
2025-07-03 07:00
Share Issue/Capital Change
Idag inleds teckningsperioden i IRLAB:s företrädesemission av aktier
Swedish 57.4 KB
2025-07-02 15:00
Prospectus
IRLAB offentliggör informationsdokument i samband med företrädesemissionen
Swedish 56.0 KB
2025-07-02 15:00
Share Issue/Capital Change
IRLAB publishes information document in connection with the rights issue
English 56.0 KB
2025-06-24 07:57
Share Issue/Capital Change
The Board of Directors of IRLAB has resolved on an 85 per cent secured rights i…
English 75.6 KB
2025-06-24 07:57
Share Issue/Capital Change
IRLAB genomför en till 85 procent garanterad företrädesemission om cirka 136 MS…
Swedish 75.2 KB
2025-06-11 18:30
Post-Annual General Meeting Information
Kommuniké från årsstämman 2025 i IRLAB Therapeutics AB
Swedish 45.8 KB
2025-06-11 18:30
Post-Annual General Meeting Information
Report from the Annual General Meeting 2025 of IRLAB Therapeutics AB
English 44.5 KB
2025-05-12 08:30
Pre-Annual General Meeting Information
KALLELSE TILL ÅRSSTÄMMA I IRLAB THERAPEUTICS AB
Swedish 65.6 KB

Automate Your Workflow. Get a real-time feed of all IRLAB Therapeutics filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for IRLAB Therapeutics via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-05 Kristina Torfgård Other Buy 9,000 140,850.00 SEK
2024-08-05 Kristina Torfgård Other Buy 4,500 70,875.00 SEK
2024-05-14 Gunnar Olof Olsson Other Buy 2,000 31,000.00 SEK
2024-05-10 Daniel Johnsson Other Buy 20,000 259,680.00 SEK
2023-04-03 Joakim Tedroff Other Buy 51,430 2,038,685.20 SEK
2022-09-01 Richard Godfrey Other Buy 5,000 174,457.00 SEK
2022-08-30 Viktor Siewertz Other Buy 40 1,420.00 SEK
2022-08-29 Viktor Siewertz Other Sell 40 1,408.00 SEK
2022-07-15 Joakim Tedroff Other Other 84,148 N/A
2022-05-31 Viktor Siewertz Other Buy 4,500 170,370.00 SEK

Peer Companies

Company Country Ticker View
Purple Biotech Ltd. Logo
Develops first-in-class cancer therapies targeting tumor immune evasion and drug resistance.
Israel PPBT
Develops uncopiable atomic fingerprints for anti-counterfeiting, verifiable by smartphone.
United Kingdom N/A
QUANTUM BLOCKCHAIN TECHNOLOGIES PLC Logo
R&D firm using AI and quantum computing to create efficient technologies for Bitcoin mining.
United Kingdom QBT
Quantum Genomics Logo
Develops digital twin solutions to simulate drug effects and personalize treatments.
France ALQGC
QUIA PHARMA AB Logo
Develops enhanced drugs using a patented, releasable pegylation drug delivery platform.
Sweden QUIA
Read Gene Spolka Akcyjna Logo
Develops DNA tests to identify genetic cancer risk for early detection and prevention.
Poland RDG
RELIEF Therapeutics Holding AG Logo
Developing and commercializing novel therapies for rare and ultra-rare diseases.
Switzerland RLF
Respiratorius AB Logo
Developing innovative drug candidates to enhance standard therapies for aggressive cancers.
Sweden RESP
ROQUEFORT THERAPEUTICS PLC Logo
Developing novel immuno-oncology medicines for hard-to-treat, resistant cancers.
United Kingdom ROQ
United States of America N/A